|
業務類別
|
Biotechnology |
|
業務概覽
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE). |
| 公司地址
| 2855 Gazelle Court, Carlsbad, CA, USA, 92010 |
| 電話號碼
| +1 760 931-9200 |
| 傳真號碼
| +1 760 268-4922 |
| 公司網頁
| https://www.ionis.com |
| 員工數量
| 1402 |
| Mr. Eric E. Swayze, PhD |
Executive Vice President, Research |
美元 589.01K |
23/04/2026 |
| Dr. Brett P. Monia, PhD |
Chief Executive Officer and Director |
美元 1.05M |
23/04/2026 |
| Ms. Elizabeth L. Hougen |
Executive Vice President, Finance, Principal Accounting Officer and Chief Financial Officer |
美元 729.75K |
23/04/2026 |
| Mr. Patrick R. O'Neil, Esq. |
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary |
美元 611.79K |
23/04/2026 |
| Ms. Shannon L. Devers |
Executive Vice President and Chief Human Resources Officer |
-- |
23/04/2026 |
| Mr. Joseph T. Baroldi |
Executive Vice President and Chief Business Officer |
-- |
23/04/2026 |
| Dr. C. Frank Bennett,PhD |
Executive Vice President and Chief Scientific Officer |
-- |
23/04/2026 |
| Mr. Kyle Jenne |
Executive Vice President and Chief Global Product Strategy Officer |
-- |
23/04/2026 |
| Dr. Holly B. Kordasiewicz, PhD |
Executive Vice President and Chief Development Officer |
-- |
23/04/2026 |
| Mr. Brian Birchler |
Executive Vice President, Corporate and Development Operations |
美元 580.15K |
23/04/2026 |
| Mr. Eugene Schneider |
Executive Vice President and Chief Clinical Development and Operations Officer |
-- |
23/04/2026 |
|
|
| Ms. B. Lynne Parshall, Esq.,J.D. |
Director |
09/03/2026 |
| Mr. Joseph H. Wender |
Lead Independent Director |
09/03/2026 |
| Mr. Joseph Klein, III |
Independent Director |
23/04/2026 |
| Dr. Joseph Loscalzo, M.D.,PhD |
Chairman of the Board |
23/04/2026 |
| Ms. Joan E. Herman |
Independent Director |
23/04/2026 |
| Dr. Spencer R. Berthelsen,M.D. |
Independent Director |
23/04/2026 |
| Dr. Michael Hayden, PhD |
Independent Director |
23/04/2026 |
| Dr. Brett P. Monia, PhD |
Chief Executive Officer and Director |
23/04/2026 |
| Mr. Michael J. Yang |
Independent Director |
23/04/2026 |
| Ms. Allene M. Diaz |
Independent Director |
23/04/2026 |
| Mr. Peter N. Reikes |
Director |
09/03/2026 |
|
|
|
|
